Dr. Michael J Overman, MD
Claim this profileM D Anderson Cancer Center
Studies Solid Tumors
Studies Colorectal Cancer
10 reported clinical trials
20 drugs studied
Area of expertise
1Solid Tumors
dMMR positive
MSI-H positive
Stage III
2Colorectal Cancer
Stage IV
dMMR positive
MSI-H positive
Affiliated Hospitals
Clinical Trials Michael J Overman, MD is currently running
Nous-209 Vaccine
for Metastatic Cancer
Ref: Protocol v9.0, dated 7Nov2023. NOUS-209-01 is a multicenter, open-label, multiple cohorts, clinical study, designed to evaluate safety, tolerability, and immunogenicity, and to detect any preliminary evidence of anti-tumor activity of Nous-209 genetic polyvalent vaccine plus pembrolizumab combination therapy in adult subjects with unresectable or metastatic deficient mismatch repair (dMMR) or MSI-H CRC, gastric, or gastro-esophageal junction (G-E junction) tumors. Nous-209 is based on a heterologous prime/boost regimen composed of the Great Ape Adenovirus GAd20-209-FSP used for priming and Modified Vaccinia virus Ankara MVA-209-FSP used for boosting. The Phase I portion of the study is a first-in-human (FIH) clinical study with a primary objective to elucidate the safety and tolerability of Nous-209 in addition to establishing the recommended Phase 2 dose (RP2D), whereas the Phase II was introduced to assess efficacy as the primary objective.
Recruiting1 award Phase 1 & 225 criteria
Cemiplimab
for Colon Cancer
To learn if cemiplimab can help to control dMMR colon cancer.
Recruiting1 award Phase 2
More about Michael J Overman, MD
Clinical Trial Related3 years of experience running clinical trials · Led 10 trials as a Principal Investigator · 6 Active Clinical TrialsTreatments Michael J Overman, MD has experience with
- Pembrolizumab
- Fluorouracil
- Leucovorin
- Nivolumab
- Synthetic Tumor-Associated Peptide Vaccine Therapy
- Nous-209
Breakdown of trials Michael J Overman, MD has run
Solid Tumors
Colorectal Cancer
Adenocarcinoma
Tumors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Michael J Overman, MD specialize in?
Michael J Overman, MD focuses on Solid Tumors and Colorectal Cancer. In particular, much of their work with Solid Tumors has involved dMMR positive patients, or patients who are MSI-H positive.
Is Michael J Overman, MD currently recruiting for clinical trials?
Yes, Michael J Overman, MD is currently recruiting for 6 clinical trials in Houston Texas. If you're interested in participating, you should apply.
Are there any treatments that Michael J Overman, MD has studied deeply?
Yes, Michael J Overman, MD has studied treatments such as Pembrolizumab, Fluorouracil, Leucovorin.
What is the best way to schedule an appointment with Michael J Overman, MD?
Apply for one of the trials that Michael J Overman, MD is conducting.
What is the office address of Michael J Overman, MD?
The office of Michael J Overman, MD is located at: M D Anderson Cancer Center, Houston, Texas 77030 United States. This is the address for their practice at the M D Anderson Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.